December 12, 2022 Asieris Enrolled First Patient for its Phase II Clinical Study of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
December 12, 2022 Asieris’Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study
November 14, 2022 Asieris named “2022 TOP 20 Most Influential Innovative Enterprises in Small Molecule Drugs”
November 11, 2022 The Oral APL-1202 in Combination with PD-1 inhibitor Tislelizumab as Neoadjuvant Therapy has Entered Phase II Clinical Study
November 10, 2022 Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
November 4, 2022 Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial
September 15, 2022 Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance
August 25, 2022 Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy
December 27, 2021 Bladder cancer diagnosis drug Hexvix® completed first patient procedure in Bo’ao Lecheng
October 13, 2021 The CDE Approved IND Application to Investigate Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients
September 26, 2021 Asieris Named One of Top 30 Chinese Innovative Enterprises in Small Molecule Drugs
September 22, 2021 Asieris Appoints Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research
June 22, 2021 Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®
June 14, 2021 The U.S. FDA Approved IND Application to Investigate Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients
May 20, 2021 Asieris and Sinopharm Enter into Strategic Partnership to Accelerate Commercialization of Asieris Products
May 6, 2021 Asieris and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of APL-1202 and Tislelizumab
April 8, 2021 Asieris Appoints Dr. Tie-Lin Wang as Senior Vice President, Head of Discovery Chemistry and Pre-Clinical Development
January 26, 2021 Asieris and Photocure Expand Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan
January 25, 2021 Asieris Appointed Dr. Yong Xue as Chief Medical Officer and Mr. Xinming Jiang as VP of Sales and Marketing
November 12, 2020 Asieris Announces First Patient Enrollment in the Global Phase III Clinical Trial for APL-1702
October 30, 2020 Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC)
July 8, 2020 Asieris Received China NMPA’s Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL)
July 1, 2020 Asieris Appointed Dr. Susan Wang as Senior Vice President of Global Business Development
June 28, 2020 Asieris Announced the Completion of Series C+ Round Financing – to Accelerate the Commercialization
March 24, 2020 Asieris Announced the Completion of Series C Round Financing- to Accelerate the Global Development of Its Innovative Drugs
July 2, 2019 Asieris and Photocure Enter into a License Agreement for World-Wide Development and Commercialization of Cevira®
March 21, 2019 Asieris’s Executives to Participate in the Upcoming Asia Pharma R&D Leaders Summit 2019
